Bicycle Therapeutics Future Growth
Future criteria checks 2/6
Bicycle Therapeutics is forecast to grow earnings and revenue by 3.2% and 50.2% per annum respectively. EPS is expected to grow by 11.1% per annum. Return on equity is forecast to be -157.1% in 3 years.
Key information
3.2%
Earnings growth rate
11.1%
EPS growth rate
Biotechs earnings growth | 31.8% |
Revenue growth rate | 50.2% |
Future return on equity | -157.1% |
Analyst coverage | Good |
Last updated | 09 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 48 | -290 | -263 | -182 | 9 |
12/31/2025 | 28 | -265 | -255 | -169 | 11 |
12/31/2024 | 28 | -228 | -211 | -173 | 13 |
12/31/2023 | 27 | -181 | -64 | -61 | N/A |
9/30/2023 | 25 | -162 | -48 | -44 | N/A |
6/30/2023 | 23 | -140 | -55 | -48 | N/A |
3/31/2023 | 15 | -124 | -122 | -106 | N/A |
12/31/2022 | 14 | -113 | -105 | -86 | N/A |
9/30/2022 | 15 | -101 | -85 | -66 | N/A |
6/30/2022 | 16 | -87 | -54 | -39 | N/A |
3/31/2022 | 14 | -78 | -34 | -27 | N/A |
12/31/2021 | 12 | -67 | -17 | -15 | N/A |
9/30/2021 | 12 | -66 | -22 | -21 | N/A |
6/30/2021 | 11 | -62 | -54 | -53 | N/A |
3/31/2021 | 11 | -56 | -54 | -53 | N/A |
12/31/2020 | 10 | -51 | -19 | -18 | N/A |
9/30/2020 | 12 | -38 | -7 | -6 | N/A |
6/30/2020 | 9 | -37 | -8 | -7 | N/A |
3/31/2020 | 9 | -35 | -4 | -2 | N/A |
12/31/2019 | 14 | -31 | -30 | -29 | N/A |
9/30/2019 | 10 | -33 | -34 | -33 | N/A |
6/30/2019 | 11 | -31 | -28 | -26 | N/A |
3/31/2019 | 11 | -26 | -25 | -24 | N/A |
12/31/2018 | 7 | -22 | -27 | -26 | N/A |
9/30/2018 | 7 | -21 | -20 | -19 | N/A |
12/31/2017 | 2 | -16 | -3 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 50BA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 50BA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 50BA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 50BA's revenue (50.2% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 50BA's revenue (50.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 50BA is forecast to be unprofitable in 3 years.